Open AccessPharmacogenetic interactions between antiretroviral drugs and vaginally administered hormonal contraceptives
Author(s) -
David W. Haas,
Yoninah Cramer,
Catherine Godfrey,
Susan L. Rosenkranz,
Francesca Aweeka,
Baiba Berzins,
Robert W. Coombs,
Kristine Coughlin,
Laura Moran,
David Gingrich,
Carmen Zorrilla,
Paxton Baker,
Susan E. Cohn,
Kimberly K Scarsi
Publication year - 2020
Publication title -
pharmacogenetics and genomics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.579
H-Index - 140
eISSN - 1744-6880
pISSN - 1744-6872
DOI - 10.1097/fpc.0000000000000396
Subject(s) - efavirenz , etonogestrel , ritonavir , nevirapine , pharmacology , atazanavir , medicine , cyp2b6 , population , pharmacokinetics , endocrinology , viral load , virology , cyp3a4 , human immunodeficiency virus (hiv) , family planning , antiretroviral therapy , environmental health , cytochrome p450 , metabolism , research methodology
In AIDS Clinical Trials Group study A5316, efavirenz lowered plasma concentrations of etonogestrel and ethinyl estradiol, given as a vaginal ring, while atazanavir/ritonavir increased etonogestrel and lowered ethinyl estradiol concentrations. We characterized the pharmacogenetics of these interactions.